ArticleScientific reports2019
C-terminal-modified LY2510924: a versatile scaffold for targeting C-X-C chemokine receptor type 4.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Selective CXCR4-Targeting Radioconjugates Derived from LY2510924: Evaluation of [Pharmaceuticals (Basel, Switzerland) · 2026Article
- CXCR4: A Promising Novel Strategy for Lung Cancer Treatment.Biomolecules · 2026Review
- Optimization of next-generation CXCR4 ligands for radiotheranostic applications.Frontiers in pharmacology · 2026Review
- CXCR4-targeted theranostics in acute leukemia: disrupting leukemic cell-microenvironment interactions with pentixafor and pentixather.Medical oncology (Northwood, London, England) · 2025Review
- Targeting the chemokine receptor CXCR4 for cancer therapies.Biomarker research · 2025Review
- Selective PET imaging of CXCR4 using the AlEuropean journal of nuclear medicine and molecular imaging · 2025Article
- CXCR4 as a therapeutic target in acute myeloid leukemia.Leukemia · 2024Review
- Research Progress of CXCR4-Targeting Radioligands for Oncologic Imaging.Korean journal of radiology · 2023Review
- CXCR4-Targeted Radiopharmaceuticals for the Imaging and Therapy of Malignant Tumors.Molecules (Basel, Switzerland) · 2023Review
- Recent Advances in CXCL12/CXCR4 Antagonists and Nano-Based Drug Delivery Systems for Cancer Therapy.Pharmaceutics · 2022Review
- In Vivo Targeting of CXCR4-New Horizons.Cancers · 2021Review
- D-Peptide-Based Probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy.Pharmaceutics · 2021Article
- New Insights on the Emerging Genomic Landscape of CXCR4 in Cancer: A Lesson from WHIM.Vaccines · 2020Review
- Targeting CXCR4 in AML and ALL.Frontiers in oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
C-X-C chemokine receptor type 4 (CXCR4) constitutes a promising target for tumor diagnosis and therapy. Herein, we evaluate a new 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-conjugated CXCR4 antagonist derived from LY2510924, FRM001, and its metal complexes as CXCR4-targeting probes. FRM001 was synthesized by modifying the C-terminus of LY2510924 with maleimido-mono-amide-DOTA via a cysteine linker. FRM001 exhibited CXCR4-specific binding with an affinity similar to that of the parental LY2510924. The binding affinity of FRM001 remained unchanged after complexation with Ga, Lu, and Y. The internalization of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.